In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

The move drew sharp criticism from medical and health experts. “Scrapping the fastest platform we have is a reckless move ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

This includes terminating awards and contracts with pharmaceutical companies and universities and canceling 22 investment ...

Several vaccines for HIV have been tested in animal studies and an early safety trial in people, showing promising results in ...

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

There have been no changes to the licensing and royalty agreements related to mRNA research that have netted the university ...

While no mRNA vaccine for cancer has gained approval from the U.S. Food and Drug Administration, there’s hope that the success of COVID-19 vaccines will help accelerate clinical research.

Researchers will monitor 56 HIV-negative adults for six months in the Phase 1 clinical trial, typically the first step in a long road to study the safety and efficacy of a vaccine.